La Jolla Pharmaceutical (LJPC) Announces Negative Results of Interim Efficacy Analysis for Riquent Phase 3 ASPEN Trial
More News related to LJPC
- La Jolla Pharmaceutical Company Announces the Adjournment of Special Meeting of Stockholders
- La Jolla Pharmaceutical (LJPC) Adjourns Special Meeting of Shareholders
- La Jolla Pharmaceutical Company Announces the Adjournment of Special Meeting of Stockholders
- La Jolla Pharmaceutical Company to Seek Stockholder Approval of Dissolution
- La Jolla Pharmaceutical Company Receives Notice of Noncompliance with Nasdaq Stock Market Listing Requirement
More News related to Corporate News
- Morgan Stanley Upgrades CHU to Overweight, Downgrades CHL, CHA to Equal Weight
- Goldman Sachs Upgraded Questar Corp. (STR) to Buy
- Avondale Securities Upgrades J.B. Hunt Transport (JBHT) to Outperform
- BMO Capital Upgrades Suncor Energy (SU) to Outperform
- MF Global Upgrades ArcelorMittal (MT) to Buy
La Jolla Pharmaceutical Company (Nasdaq: LJPC) announced that the Independent Data Monitoring Board for the Riquent(R) Phase 3 ASPEN study has informed the Company that they have completed the first interim efficacy analysis and determined that continuing the study is futile. The Company has decided to stop the study, unblind the data and evaluate the results. The Company expects to provide additional guidance on its strategic options going forward in the near future.
Related Categories
Corporate NewsFDA
Stocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
